Metabasis Therapeutics (MBRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX)

MBRX 0.467

+3.3%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sjemmeri who wrote (15)	10/26/2006 5:02:54 PM
From: sjemmeri	of 66

Metabasis Therapeutics announces research collaboration with Idenix to develop compounds for the treatment of Hepatitis C Briefing.com - October 26, 2006 4:06 PM ET Co announces a two-year research collaboration agreement with Idenix Pharmaceuticals (IDIX) Under the terms of the agreement, MBRX's HepDirect liver-targeting technology will be applied to proprietary IDIX compounds to develop second-generation nucleoside analog drug candidates for the treatment of hepatitis C virus. Under the terms of the agreement, IDIX will provide preclinical drug candidates and a $2.0 mln upfront payment, and fund all activities at MBRX related to the collaborative discovery efforts. In the event a lead is identified, Idenix will assume development responsibility and Metabasis will be eligible to receive up to $23.5 mln upon achievement of predetermined preclinical and clinical development milestones and an additional $40.0 mln based on regulatory approvals. For any marketed products that result from the collaboration, IDIX will retain full commercial rights and pay Metabasis a royalty on net sales.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next